This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies) represents the fourth time that Kalorama Information has taken a comprehensive look at oncology therapeutics. The report focuses on several segments for cancer treatment including:
- Chemotherapy, - Subcategories include Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives - Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar, with Market Share for each
- Hormone Therapy: - Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS - Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron, with Market Share for each
- Immunotherapy and Biotherapy, including: -Monoclonal antibodies, Interleukins/interferons, Vaccines and Other Biotherapies - Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux
One of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. The report devotes particular attention to these new therapies.
This report, Kalorama's fourth complete research effort into the oncology treatments market in the past ten years, provides market size information for the various types of cancers including the following:
- Bladder
- Breast
- Cervical
- Colorectal
- Esophageal
- Head/Neck
- Kidney
- Leukemia
- Liver
- Lung
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian
- Pancreatic
- Prostate
- Stomach
The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview, description of products on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the industry.
As part of its coverage, the report looks at the following trends
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol’s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Obesity in the U.S.
- Outlook for a Healthier U.S. Population
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends (US, Europe, Japan)
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2010. Historical data was provided for the years 2005 through 2009, with forecast data provided for 2011 through 2015. Compound annual growth rates (CAGRs) are provided for the 2005-2010, 2010-2015 and 2005-2015 periods for each industry segment covered. Competitive analysis is provided for the year 2010. The forecasted market analysis for 2010-2015 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
Tyrosine kinase inhibitors such as Gleevac and Nexavar represent the fastest growing segment in the market for cancer treatments and have boosted the performance of many pharmaceutical companies, according to Kalorama Information. The healthcare market research publisher estimated the world market for cancer therapies to be $54.4 billion in 2010 in its latest report, The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition.
"Growth in cancer biotherapies spiked in the last five years, taking share from hormone and chemotherapy sales," said Bruce Carlson, publisher of Kalorama Information. "And within that category, tyrosine kinase inhibitors have demonstrated effectiveness and thus they've been growing fast in terms of sales."
Mutations in receptor tyrosine kinases cause cell proliferation and human disease. Drugs such as Iressa, Tarceva, Tykerb, Sprycel, Tasigna, Sutent and the segment's newest product Votrient, have been shown to inhibit the function of these receptors and thus mitigate the unusual cell growth that represents cancer. Sales will likely remain strong with research and development efforts focused on these newer therapies. In the last five years, Kalorama estimates that tyrosine kinase inhibitors grew by nearly 26.7%, faster than any other cancer treatment.
The report notes that a rising incidence of cancer, particularly in the over 50 population, is likely having a significant impact on all areas of cancer treatment. However, for many cancer types, there remains a significant unmet need in effective treatment. Lung cancer is one example, as patient survival is less than five years after diagnosis. The report covers new therapies that are in development.
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
- What is Cancer
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- History and Growth of the Cancer Treatment Market
- Industry Structure
- Product Segments and Technology
- Chemotherapy: At a Glance
- Hormone Therapy: At A Glance
- Biotherapy: At A Glance
- Radiation Therapy: At a Glance
- Demographics and Statistics
- Global Cancer Statistics
- Demographics
- Aging Population
- Life Expectancy and Cancer
- Life Expectancy
- Birth Rates
- Description of Cancers
- Bladder Cancer
- Brain Cancer
- Glioblastoma
- Neuroblastoma
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Ovarian Cancer
- Pancreas
- Prostate Cancer
- Stomach Cancer
- Overview
- Product Descriptions and Examples
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- European Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
- Overview
- Product Descriptions and Examples
- Corticosteroids
- Hormone Agonists and Antagonists
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
- Overview
- Product Descriptions and Examples
- Monoclonal Antibodie
- Interleukins/Interferons
- Tyrisoine Kinase Inhibitors
- Other Biotherapeutics
- Radioimmunotherapy
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
- Overview
- Total Market Size and Forecast
- Geographical Market Distribution
- Competitive Landscape
- Introduction
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol’s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Obesity in the U.S.
- U.S. Obesity Rates Differ Among Ethnic Groups
- Outlook for a Healthier U.S. Population
- Obesity in the U.S.
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends
- United States
- Europe
- Japan
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
- Significant Developments
- Alpharadin
- Afatinib
- Axitinib
- Bosutinib
- Brentuximab
- Carfilzomib
- Crizotinib
- Erwinaze
- Exelbine
- Motesanib
- Omnitarg
- Regorafenib
- Ridaforolimus
- Zaltrap
- Significant Developments
- Recent NDA Activity
- New Approvals
- Introduction
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi
- Table 1-1: World Cancer Market
- Table 1-2: Market by Product Type (Chemotherapy, Hormone Therapy,
Biotherapeutics), 2005-2015
- Figure 1-1: World Cancer Market, Market by Product Type (Chemotherapy,
Hormone Therapy, Biotherapeutics), 2005-2015
- Figure 1-2: World Cancer Market, Market by Product Type and Percent Market Share, 2010
- Table 2-1: Viruses Associated with Cancer in Humans
- Figure 2-1: Approved Cancer Therapies in the United States by
Primary Indication
- Table 2-2: World Cancer Incidence by Selected Types of Cancer, 2010
and 2020, (Lung,Breast, Colon/ Rectum, Stomach, Liver, Prostate,
Cervical, Ovarian, Lymphoma, Pancreatic, Melanoma)
- Figure 2-2: Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2010 and 2020
- Table 2-3: Total Cancer Incidence by Sex and Country(Canada, China,
France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom,
United States), 2010 Estimates
- Figure 2-3: Total Cancer Incidence by Sex and Country(Canada, China,
France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom,
United States), 2010 Estimates
- Table 2-4: World Population by Selected Geographical Region(Africa, Asia,
Europe, North America, Oceania, South America, World), 2010 - 2050
- Figure 2-4: World Population by Selected Geographical Region(Africa, Asia,
Europe, North America, Oceania, South America, World), 2010-2050
- Table 2-5: Percent Population Over 65 by Year and Region, 2010-2050
- Figure 2-5: Estimated World Population by Age, 2010 and 2050
- Table 2-6: Average Life Expectancy in Years by Country 1980, 2004 and 2009
- Figure 2-6: Average Life Expectancy in Years by Country 1980 and 2009
- Figure 2-7: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2006
- Figure 2-8: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2006
- Table 2-7: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
- Figure 2-9: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
- Table 2-9: Types of Leukemia
- Table 2-9: Types of Primary Lung Cancer
- Table 2-10: Classification of Non-Hodgkin’s Lymphomas
- Table 2-11: Malignant Conditions of the Skin
- Table 3-1: Leading Products, 2010
- Table 3-2: World Chemotherapy Market, 2005-2015
- Figure 3-1: World Chemotherapy Market, 2005-2015
- Table 3-3: World Chemotherapy Market, Sales by Drug Classification,
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives) 2010
- Figure 3-2: World Chemotherapy Market by Drug Classification,
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives)
- Table 3-4: World Chemotherapy Market, Sales by Drug Classification
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives),
Estimated 2010)
- Figure 3-3: World Chemotherapy Market by Drug Classification
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives),
Estimated 2015
- Figure 3-4: World Chemotherapy Current Market by Region (US, EU,
Japan, ROW)
- Figure 3-5: World Chemotherapy Market by Region 2015 (US, EU,
Japan, ROW)
- Table 3-5: World Chemotherapy Market Type by Cancer Type (Lung, Breast,
Colon, Brain, Ovarian, Other Total)
- Figure 3-6: World Chemotherapy Market by Cancer Type (Lung, Breast,
Colon, Brain, Ovarian, Other Total)
- Table 3-6: World Chemotherapy Market, Leading Suppliers Shares
by Market Revenues, 2010
- Figure 3-7: World Chemotherapy Market, Leading Suppliers Market Share, 2010
CHAPTER FOUR: HORMONE THERAPY
- Table 4-1: Leading Products, 2010
- Table 4-2: World Hormone Therapy Market, 2005-2015
- Figure 4-1: World Hormone Therapy Market, 2005-2015
- Table 4-3: World Hormone Therapy Market, Sales by Drug Classification (
Corticosteroids, Hormone agonists/ Antagonists, Aromatase Inhibitors,
SERMs), 2010
- Figure 4-2: World Hormone Therapy Market, Market by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors,
SERMs) and Percent Market Share, 2010
- Table 4-4: World Hormone Therapy Market, Sales by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors
, SERMs), Estimated 2015
- Figure 4-3: World Hormone Therapy Market, Market by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors,
SERMs) and Percent Market Share, 2015
- Figure 4-4: World Hormone Therapy Current Market by Region (US, EU,
Japan, ROW)
- Figure 4-5: World Hormone Therapy Market by Region 2015 (US, EU,
Japan, ROW)
- Table 4-5: World Hormone Therapy Market by Cancer Type (Breast, Prostate,
Other)
- Figure 4-6: World Hormone Therapy Market by Cancer Type (Breast, Prostate,
Other)
- Table 4-6: World Hormone Therapy Market, Leading Suppliers Shares by
Market Revenues, 2010
- Figure 4-7: World Hormone Therapy Market, Leading Suppliers Market Share, 2010
CHAPTER FIVE: BIOTHERAPEUTICS
- Table 5-1: Leading Biopharmaceutical Cancer Treatment Products
(Brand Name, Generic Name, Manufacturer/ Marketer,
Common Uses, Annual Sales ), 2010
- Table 5-2: World Cancer Biotherapeutics Market, 2005-2015
- Figure 5-1: World Cancer Biotherapeutics Market, 2005-2015
- Table 5-3: World Biotherapeutics Market, Sales by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase
Inhibitors, Other Biotherapeutics), 2010
- Figure 5-2: World Biotherapeutics Market by Drug Classification (Monoclonal
Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics)
- Table 5-4: World Biotherapeutics Market, Sales by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase
Inhibitors, Other Biotherapeutics), Estimated 2015
- Figure 5-3: World Biotherapeutics Market by Drug Classification (Monoclonal
Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics), Estimated 2015
- Figure 5-4: World Cancer Biotherapeutics Market by Region (US, EU,
Japan, ROW)
- Figure 5-5: World Cancer Biotherapeutics Market by Region (US, EU,
Japan, ROW) , Estimated 2015
- Table 5-5: World Cancer Biotherapeutics Market by Cancer Type (Colon,
Breast, Lymphoma, Leukemia, Others)
- Figure 5-6: World Cancer Biotherapeutics Market by Cancer Type(Colon,
Breast, Lymphoma, Leukemia, Others)
- Table 5-6: World Biotherapeutics Market, Leading Suppliers
Shares by Market Revenues, 2010
- Figure 5-7: World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2010
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Table 6-1: World Cancer Market, Market by Product Type, 2005-2015
- Figure 6-1: World Cancer Market, Market by Product Type Revenues, 2005-2015
- Figure 6-2: World Cancer Market, Market by Product
Type and Percent Market Share, 2010
- Figure 6-3: World Cancer Market, Market by Product Type and Percent
Market Share, 2015
- Table 6-2: World Cancer Market, Leading Suppliers’ Shares by Market
Revenues, 2010
- Figure 6-5: World Cancer Market, Leading Suppliers’ Market Share, 2010
- Table 7-1: Obesity Rates by U.S. State, 2009
- Table 7-2: Select Products in Development by Development Phase
- Figure 7-1: Late Stage Cancer Compounds in Development for
Major Indications, Distribution Estimates
- Table 7-3: Recent NDA Activity: January 2011-July 2011
- Table 7-4: Select New Approvals (NCE, Indications, Dosage, Formulations) ,2010-11
CHAPTER EIGHT: CORPORATE PROFILES
- Figure 8-1: Late stage Cancer Therapies in Development for Leading Companies
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook